In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Minvera signs co-development deal for Janssen’s insomnia candidate; later opts out of agreement

Executive Summary

Minerva Neurosciences Inc. (in-licenses or acquires neurological candidates) signed a preliminary agreement for exclusive rights to develop, manufacture, and market (with right to sublicense) in the EU, Switzerland, Liechtenstein, Iceland, and Norway Janssen Pharmaceutica NV’s Phase I JNJ2847922, a selective orexin-2 antagonist for primary insomnia, and for secondary insomnia as an adjunctive with an antidepressant for the treatment of mood disorders. The compound was renamed MIN202 (seltorexant).

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies